Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, has announced it will release its second quarter 2024 financial results and corporate highlights on Tuesday, August 6, 2024, after the U.S. financial markets close. The company, known for its innovative approach to drug discovery by combining advanced computational and experimental technologies, will provide insights into its financial performance and recent developments. This announcement is significant for investors and analysts tracking Relay Therapeutics' progress in the competitive biotech sector.
Relay Therapeutics (Nasdaq: RLAY), un'azienda in fase clinica nel settore della medicina di precisione, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 e i punti salienti aziendali martedì, 6 agosto 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda, nota per il suo approccio innovativo alla scoperta di farmaci attraverso l'integrazione delle tecnologie computazionali e sperimentali avanzate, fornirà approfondimenti sulla sua performance finanziaria e sui recenti sviluppi. Questo annuncio è significativo per gli investitori e gli analisti che seguono i progressi di Relay Therapeutics nel competitivo settore biotecnologico.
Relay Therapeutics (Nasdaq: RLAY), una empresa de medicina de precisión en fase clínica, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 y aspectos destacados corporativos el martes 6 de agosto de 2024, después del cierre de los mercados financieros de EE. UU. La empresa, conocida por su enfoque innovador en el descubrimiento de medicamentos al combinar tecnologías computacionales y experimentales avanzadas, proporcionará información sobre su desempeño financiero y desarrollos recientes. Este anuncio es significativo para los inversores y analistas que siguen el progreso de Relay Therapeutics en el competitivo sector biotecnológico.
릴레이 테라퓨틱스(Relay Therapeutics)(Nasdaq: RLAY)는 임상 단계의 정밀 의학 회사로, 2024년 2분기 재정 결과 및 기업 주요 내용을 2024년 8월 6일 화요일 미국 금융 시장 마감 후 발표할 것이라고 전했습니다. 고급 컴퓨터 기술과 실험 기술을 결합한 혁신적인 약물 발견 접근 방식으로 알려진 이 회사는 재정 성과 및 최근 개발에 대한 통찰력을 제공할 예정입니다. 이 발표는 경쟁이 치열한 생명공학 분야에서 릴레이 테라퓨틱스의 진행 상황을 추적하는 투자자 및 분석가에게 중요합니다.
Relay Therapeutics (Nasdaq: RLAY), une entreprise de médecine de précision en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 et ses faits saillants corporatifs le mardi 6 août 2024, après la clôture des marchés financiers américains. Connue pour son approche innovante de la découverte de médicaments en combinant des technologies expérimentales et de calcul avancées, l'entreprise fournira des informations sur sa performance financière et ses développements récents. Cette annonce est significative pour les investisseurs et analystes suivant les progrès de Relay Therapeutics dans le secteur compétitif des biotechnologies.
Relay Therapeutics (Nasdaq: RLAY), ein Unternehmen für präzisionsmedizinische Behandlungen in der klinischen Phase, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 sowie Unternehmens-Highlights am Dienstag, den 6. August 2024, nach dem Schließen der US-Finanzmärkte veröffentlichen wird. Das Unternehmen, das für seinen innovativen Ansatz in der Arzneimittelentdeckung bekannt ist, bei dem fortschrittliche computergestützte und experimentelle Technologien kombiniert werden, wird Einblicke in seine finanzielle Performance und aktuelle Entwicklungen geben. Diese Ankündigung ist für Investoren und Analysten, die die Fortschritte von Relay Therapeutics im wettbewerbsintensiven Biotechnologiesektor verfolgen, von Bedeutung.
- None.
- None.
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 6, 2024.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo™ platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics (RLAY) release its Q2 2024 financial results?
What is Relay Therapeutics' (RLAY) stock symbol and exchange?
What type of company is Relay Therapeutics (RLAY)?
